WTX 212
Alternative Names: WTX-212Latest Information Update: 09 Jul 2024
At a glance
- Originator Westlake Therapeutics
- Class Antineoplastics; Cell therapies; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies; Solid tumours
Most Recent Events
- 31 May 2024 Efficacy, pharmacokinetics and adverse events data from a phase I Reboot-101 trial in Solid tumors presented at the60th Annual Meeting of the American Society of Clinical Oncology, 2024 (ASCO-2024)
- 05 Apr 2024 Efficacy and adverse events data from a phase I trial in Solid tumours and Haematological malignancies presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 22 Sep 2022 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater, Late-stage disease) in China (IV) (NCT05707325)